Serum CA-125 and renal impairment in patients undergoing hyperthermic intraperitoneal chemotherapy

Biomed J. 2022 Oct;45(5):847-848. doi: 10.1016/j.bj.2021.12.002. Epub 2021 Dec 11.

Authors

David Bernal-Bello¹, Ignacio Guerra-Pérez², Laura Alegre-Zahonero³

Affiliations

¹ Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain. Electronic address: david.bernal@salud.madrid.org.
² Department of Medical Specialities and Public Health, Universidad Rey Juan Carlos, Madrid, Spain.
³ Department of Medical Specialities and Public Health, Universidad Rey Juan Carlos, Madrid, Spain; Department of Nephrology, Hospital Universitario de Fuenlabrada, Madrid, Spain.

No abstract available

Keywords: CA-125; Drug toxicity; HIPEC; Peritoneal permeability; Renal failure.

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cisplatin*
Humans
Hyperthermic Intraperitoneal Chemotherapy*
Survival Rate

Substances

Cisplatin